Trial Profile
Characterization and Modulation of Mucosal Immunity for HIV Prevention in Women
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Maraviroc (Primary) ; Emtricitabine/tenofovir disoproxil fumarate
- Indications HIV infections
- Focus Pharmacodynamics
- Acronyms MIP
- 15 Nov 2017 Status changed from recruiting to discontinued.
- 04 Aug 2016 Planned End Date changed from 1 Jan 2020 to 1 Jan 2022.
- 26 Jan 2016 Changed planned patient number and treatment arms , as reported by ClinicalTrials.gov record.